The company uses proprietary protein nanoparticles to create powerful immunotherapies that target cancer, with their initial product improving response rates to checkpoint inhibitors for solid tumors. Bullet Biotechnology's capsid platform can also be used to create vaccines and explore other combination immunotherapies, all while taking a practical approach to building and realizing value for patients and investors. For more information, contact Bullet Bio at [email protected].